TY - JOUR
T1 - Cytotoxicity of HA-TCP Scaffold on Human Umbilical Cord Mesenchymal Stem Cells using MTT Assay
AU - Ariestania, Vivin
AU - Hendrijantini, Nike
AU - Prahasanti, Chiquita
AU - Prasetyo, Eric
AU - Kuntjoro, Mefina
AU - Sari, Rima Parwati
AU - Maharani, Aulia Dwi
N1 - Publisher Copyright:
© 2022. UTHM Publisher. All rights reserved.
PY - 2022
Y1 - 2022
N2 - Hydroxyapatite-tricalcium phosphate (HA-TCP) scaffold is a three-dimensional structure used to support bone regeneration. Ideally, the scaffold should be biocompatible, biodegradable, and non-toxic. The tissue engineering technique uses a combined stem cell and scaffold to repair the bone defect. To prove the non-toxic properties of the scaffold, a cytotoxicity test is needed for the human umbilical cord mesenchymal stem cell (HUCMSCs). In this study, 27 samples were divided into eight groups with a variant of scaffold HA-TCP doses ranging from 5–1000 μg. Each treatment group of scaffolds was covered in HUCMSCs. The samples were added by methyl-thiazol-tetrazolium (MTT) colorimetric assay, counted using an optical density (OD) formula, and observed by a microplate reader. The viability of the cells was observed by an inverted TMS microscope with 100x magnification. The MTT assay’s test shows that the HUCMSCs cell viability shed each variant of HA-TCP scaffold dose, did not show any toxic effect. The higher the OD value, the higher the viability. It has been found that there is no significant difference between the variable scaffold doses to the percentage viability of umbilical cord cells.
AB - Hydroxyapatite-tricalcium phosphate (HA-TCP) scaffold is a three-dimensional structure used to support bone regeneration. Ideally, the scaffold should be biocompatible, biodegradable, and non-toxic. The tissue engineering technique uses a combined stem cell and scaffold to repair the bone defect. To prove the non-toxic properties of the scaffold, a cytotoxicity test is needed for the human umbilical cord mesenchymal stem cell (HUCMSCs). In this study, 27 samples were divided into eight groups with a variant of scaffold HA-TCP doses ranging from 5–1000 μg. Each treatment group of scaffolds was covered in HUCMSCs. The samples were added by methyl-thiazol-tetrazolium (MTT) colorimetric assay, counted using an optical density (OD) formula, and observed by a microplate reader. The viability of the cells was observed by an inverted TMS microscope with 100x magnification. The MTT assay’s test shows that the HUCMSCs cell viability shed each variant of HA-TCP scaffold dose, did not show any toxic effect. The higher the OD value, the higher the viability. It has been found that there is no significant difference between the variable scaffold doses to the percentage viability of umbilical cord cells.
KW - Cytotoxicity
KW - Hydroxyapatite tricalcium phosphate
KW - Methyl-thiazol-tetrazolium assay
KW - Scaffold
KW - Umbilical cord mesenchymal stem cells
UR - http://www.scopus.com/inward/record.url?scp=85132578675&partnerID=8YFLogxK
U2 - 10.30880/ijie.2022.14.012
DO - 10.30880/ijie.2022.14.012
M3 - Article
AN - SCOPUS:85132578675
SN - 2229-838X
VL - 14
SP - 80
EP - 85
JO - International Journal of Integrated Engineering
JF - International Journal of Integrated Engineering
IS - 2
ER -